The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02327819

Enrollment

Registered

2014-12-30

Start date

2015-01-31

Completion date

Unknown

Last updated

2014-12-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Liver Cancer

Brief summary

Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown. The participants (post curative intent surgery) will be supplemented with either BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until a new liver tumor is found.

Interventions

DIETARY_SUPPLEMENTBranched-chain amoni acids (BCAA)

DIETARY_SUPPLEMENTnon-BCAA protein supplement

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* diagnosed primary liver cancer * viral or Nonalcoholic Steatohepatitis Cirrhosis * Cirrhosis rated Child-Pugh A * liver cancer rated Barcelona Clinic Liver Cancer (BCLC) A

Exclusion criteria

* Age (over 65) * liver condition rated Child-Pugh B/C * GI/Absorption issues * patients given a treatment before surgery

Design outcomes

Primary

Measure	Time frame
time until a new liver tumor is found	2 years

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026